KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Interest Expenses (2023 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Interest Expenses for 3 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 8.64% year-over-year to $1.0 million, compared with a TTM value of $4.3 million through Dec 2025, down 10.44%, and an annual FY2025 reading of $4.3 million, down 10.44% over the prior year.
  • Interest Expenses was $1.0 million for Q4 2025 at Aurinia Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.4 million in Q3 2023 and bottomed at $65000.0 in Q2 2023.
  • Average Interest Expenses over 3 years is $1.1 million, with a median of $1.1 million recorded in 2024.
  • The sharpest move saw Interest Expenses soared 1743.08% in 2024, then decreased 16.84% in 2025.
  • Year by year, Interest Expenses stood at $1.3 million in 2023, then decreased by 12.52% to $1.1 million in 2024, then fell by 8.64% to $1.0 million in 2025.
  • Business Quant data shows Interest Expenses for AUPH at $1.0 million in Q4 2025, $1.1 million in Q3 2025, and $1.1 million in Q2 2025.